Matches in SemOpenAlex for { <https://semopenalex.org/work/W2041402748> ?p ?o ?g. }
- W2041402748 abstract "Casein kinase 2 (CK2) is a serine/threonine kinase that has been implicated in the regulation of a number of oncogenic or tumor suppressor proteins. CK2 activity has been shown to be elevated in numerous studies in a variety of cancer types. CK2 has been shown to phosphorylate numerous cellular proteins. Among the proteins regulated directly or indirectly by CK2 phosphorylation are oncogenes and tumor suppressor proteins including beta-catenin, c-Myc, PML, and PTEN as well as proteins directly involved in cell cycle, apoptosis, and transcriptional regulation. The plethora of CK2 substrates and their participation in various cellular processes is a major confounding factor in understanding the role of CK2 in oncogenesis. Unlike other kinase targets that participate in relatively linear growth factor signaling pathways, CK2 appears to function more “laterally,” across many important signaling pathways to promote growth and survival of cancer cells. It is clear from numerous studies using siRNA as well as small molecule CK2 inhibitors that cancer cells are highly dependent upon CK2 for growth and survival. As a result, new small molecule inhibitors of CK2 may provide useful tools for probing CK2 biology and may also provide therapeutic benefits against several cancer types. Herein, we report our efforts toward the identification of CK2 inhibitors based on an imidazopyridazine carbonitrile scaffold. Lead compounds from this series demonstrate low nanomolar CK2 biochemical potency, while achieving excellent selectivity versus the majority of kinases in the human kinome. The development of structure-activity relationships and the establishment of a strong correlation between biochemical potency, inhibition of cellular protein target phosphorylation and anti-proliferative effects in targeted cancer cell lines will be presented. In addition, the optimization of pharmacokinetic properties resulting in compounds with excellent in vivo exposure has allowed for the investigation of CK2 inhibition in a pharmacodynamic model. Finally, our efforts to elucidate pathway effects mediated by CK2 in model colon cancer cell lines, including gene expression profiling using advanced small molecules leads, will be disclosed.Citation Information: Mol Cancer Ther 2013;12(11 Suppl):B284.Citation Format: Brian Fink, Ashvinikumar Gavai, Soong-Hoon Kim, Yufen Zhao, Ashok Purandare, Gregory Vite, John Tokarski, Chiang Yu, Benjamin Henley, Joseph Fargnoli, Heshani Desilva, Petra Ross-MacDonald, Brent Rupnow, Tai W. Wong. Discovery of imidazopyridazinecarbonitriles as potent, selective inhibitors of CK2. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr B284." @default.
- W2041402748 created "2016-06-24" @default.
- W2041402748 creator A5002561348 @default.
- W2041402748 creator A5006520015 @default.
- W2041402748 creator A5008519699 @default.
- W2041402748 creator A5014043601 @default.
- W2041402748 creator A5027980862 @default.
- W2041402748 creator A5032811880 @default.
- W2041402748 creator A5044912332 @default.
- W2041402748 creator A5045813781 @default.
- W2041402748 creator A5049236245 @default.
- W2041402748 creator A5061212046 @default.
- W2041402748 creator A5064763949 @default.
- W2041402748 creator A5067511503 @default.
- W2041402748 creator A5078878020 @default.
- W2041402748 creator A5085898674 @default.
- W2041402748 date "2013-11-01" @default.
- W2041402748 modified "2023-09-23" @default.
- W2041402748 title "Abstract B284: Discovery of imidazopyridazinecarbonitriles as potent, selective inhibitors of CK2." @default.
- W2041402748 doi "https://doi.org/10.1158/1535-7163.targ-13-b284" @default.
- W2041402748 hasPublicationYear "2013" @default.
- W2041402748 type Work @default.
- W2041402748 sameAs 2041402748 @default.
- W2041402748 citedByCount "0" @default.
- W2041402748 crossrefType "proceedings-article" @default.
- W2041402748 hasAuthorship W2041402748A5002561348 @default.
- W2041402748 hasAuthorship W2041402748A5006520015 @default.
- W2041402748 hasAuthorship W2041402748A5008519699 @default.
- W2041402748 hasAuthorship W2041402748A5014043601 @default.
- W2041402748 hasAuthorship W2041402748A5027980862 @default.
- W2041402748 hasAuthorship W2041402748A5032811880 @default.
- W2041402748 hasAuthorship W2041402748A5044912332 @default.
- W2041402748 hasAuthorship W2041402748A5045813781 @default.
- W2041402748 hasAuthorship W2041402748A5049236245 @default.
- W2041402748 hasAuthorship W2041402748A5061212046 @default.
- W2041402748 hasAuthorship W2041402748A5064763949 @default.
- W2041402748 hasAuthorship W2041402748A5067511503 @default.
- W2041402748 hasAuthorship W2041402748A5078878020 @default.
- W2041402748 hasAuthorship W2041402748A5085898674 @default.
- W2041402748 hasConcept C11960822 @default.
- W2041402748 hasConcept C121608353 @default.
- W2041402748 hasConcept C143910341 @default.
- W2041402748 hasConcept C184235292 @default.
- W2041402748 hasConcept C2777609662 @default.
- W2041402748 hasConcept C502942594 @default.
- W2041402748 hasConcept C54174078 @default.
- W2041402748 hasConcept C54355233 @default.
- W2041402748 hasConcept C55493867 @default.
- W2041402748 hasConcept C555283112 @default.
- W2041402748 hasConcept C62478195 @default.
- W2041402748 hasConcept C74187038 @default.
- W2041402748 hasConcept C82495950 @default.
- W2041402748 hasConcept C86554907 @default.
- W2041402748 hasConcept C86803240 @default.
- W2041402748 hasConcept C95444343 @default.
- W2041402748 hasConcept C96232424 @default.
- W2041402748 hasConcept C97029542 @default.
- W2041402748 hasConceptScore W2041402748C11960822 @default.
- W2041402748 hasConceptScore W2041402748C121608353 @default.
- W2041402748 hasConceptScore W2041402748C143910341 @default.
- W2041402748 hasConceptScore W2041402748C184235292 @default.
- W2041402748 hasConceptScore W2041402748C2777609662 @default.
- W2041402748 hasConceptScore W2041402748C502942594 @default.
- W2041402748 hasConceptScore W2041402748C54174078 @default.
- W2041402748 hasConceptScore W2041402748C54355233 @default.
- W2041402748 hasConceptScore W2041402748C55493867 @default.
- W2041402748 hasConceptScore W2041402748C555283112 @default.
- W2041402748 hasConceptScore W2041402748C62478195 @default.
- W2041402748 hasConceptScore W2041402748C74187038 @default.
- W2041402748 hasConceptScore W2041402748C82495950 @default.
- W2041402748 hasConceptScore W2041402748C86554907 @default.
- W2041402748 hasConceptScore W2041402748C86803240 @default.
- W2041402748 hasConceptScore W2041402748C95444343 @default.
- W2041402748 hasConceptScore W2041402748C96232424 @default.
- W2041402748 hasConceptScore W2041402748C97029542 @default.
- W2041402748 hasLocation W20414027481 @default.
- W2041402748 hasOpenAccess W2041402748 @default.
- W2041402748 hasPrimaryLocation W20414027481 @default.
- W2041402748 hasRelatedWork W1963529180 @default.
- W2041402748 hasRelatedWork W1976301833 @default.
- W2041402748 hasRelatedWork W2008286369 @default.
- W2041402748 hasRelatedWork W2017120709 @default.
- W2041402748 hasRelatedWork W2037260598 @default.
- W2041402748 hasRelatedWork W2041944081 @default.
- W2041402748 hasRelatedWork W2124010149 @default.
- W2041402748 hasRelatedWork W2132670577 @default.
- W2041402748 hasRelatedWork W2150692753 @default.
- W2041402748 hasRelatedWork W2171613528 @default.
- W2041402748 hasRelatedWork W2172163796 @default.
- W2041402748 hasRelatedWork W2204493619 @default.
- W2041402748 hasRelatedWork W2744255174 @default.
- W2041402748 hasRelatedWork W2786312438 @default.
- W2041402748 hasRelatedWork W2790588156 @default.
- W2041402748 hasRelatedWork W2890991666 @default.
- W2041402748 hasRelatedWork W2921050727 @default.
- W2041402748 hasRelatedWork W2954773460 @default.
- W2041402748 hasRelatedWork W3132455525 @default.
- W2041402748 hasRelatedWork W3136929512 @default.
- W2041402748 isParatext "false" @default.
- W2041402748 isRetracted "false" @default.